{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:37:53Z","timestamp":1793151473796,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"McCaig Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada"},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"crossref","award":["01ER0812, 01ER1504A, 01ER1504B, 01ER1504C"],"award-info":[{"award-number":["01ER0812, 01ER1504A, 01ER1504B, 01ER1504C"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]},{"name":"framework of the German Center for Child and Adolescent Health","award":["01GL2401C"],"award-info":[{"award-number":["01GL2401C"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03835-5","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:25:14Z","timestamp":1779769514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serological biomarkers of JIA-associated uveitis: ANA titers, ANA AC-30 staining pattern and prefoldin 5 antibodies"],"prefix":"10.1186","volume":"28","author":[{"given":"Heinrike","family":"Schmeling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatope O.","family":"Adebiyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes-Peter","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Heiligenhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Hospach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilmann","family":"Kallinich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Kuemmerle-Deschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Moenkemoeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad T.","family":"Oommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weller-Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Windschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin J.","family":"Fritzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"3835_CR1","first-page":"300","volume":"50","author":"ST Angeles-Han","year":"2023","unstructured":"Angeles-Han ST, Srivastava SK. Screening, Monitoring, and Treating Children With Juvenile Idiopathic Arthritis\u2013associated Uveitis: Visualizing Better Outcomes. J Rheumatol. 2023;50:300\u20133.","journal-title":"J Rheumatol"},{"key":"3835_CR2","first-page":"390","volume":"31","author":"E Ross","year":"2004","unstructured":"Ross E, Petty TR, Southwood P, Manners J, Baum DN, Glass J, Goldenberg X, He. Jose Maldonado-Cocco, Javier Orozco-Alcala, Anne-Marie Prieur, Maria E Suarez-Almazor PW and IL of A for R. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"3835_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5114\/reum.2020.100169","volume":"58","author":"L Rutkowska-Sak","year":"2020","unstructured":"Rutkowska-Sak L, Gietka P. Uveitis associated juvenile idiopathic arthritis \u2013 presentation of recently published international recommendations for diagnostic and therapeutic procedures. Reumatologia. 2020;58:277\u201381.","journal-title":"Reumatologia"},{"key":"3835_CR4","doi-asserted-by":"publisher","unstructured":"Solebo AL, Foeldvari I. Reducing the risk of visual disability for children with juvenile idiopathic arthritis uveitis through disease surveillance: past and future challenges. Pediatr Rheumatol. 2025;23. https:\/\/doi.org\/10.1186\/s12969-024-01037-4. Epub ahead of print.","DOI":"10.1186\/s12969-024-01037-4"},{"key":"3835_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3899\/jrheum.191085","volume":"48","author":"K Walscheid","year":"2021","unstructured":"Walscheid K, Glandorf K, Rothaus K, et al. Enthesitis-related arthritis: Prevalence and complications of associated uveitis in children and adolescents from a population-based nationwide study in Germany. J Rheumatol. 2021;48:262\u20139.","journal-title":"J Rheumatol"},{"key":"3835_CR6","unstructured":"Pooja Bhat MD, Debra A, Goldstein M, Pediatric A, Uveitis. 2021 https:\/\/www.aao.org\/education\/disease-review\/pediatric-anterior-uveitis. Accessed 5 Nov 2025."},{"key":"3835_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-021-05651-5","volume":"22","author":"AV Ramanan","year":"2021","unstructured":"Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinic. Trials. 2021;22:1\u201314.","journal-title":"Trials"},{"key":"3835_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/17469899.2020.1739521","volume":"15","author":"J Rodriguez-Smith","year":"2020","unstructured":"Rodriguez-Smith J, Yeh S, Angeles-Han ST. Improving quick and accurate diagnosis of childhood JIA-uveitis from a pediatric rheumatology perspective. Expert Rev Ophthalmol. 2020;15:101\u20139.","journal-title":"Expert Rev Ophthalmol"},{"key":"3835_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4103\/sjopt.sjopt_153_24","volume":"39","author":"C Barresi","year":"2025","unstructured":"Barresi C, Baldo F, Menean M, et al. Juvenile idiopathic arthritis and associated uveitis: A review of pathogenesis, diagnosis, and management. Saudi J Ophthalmol. 2025;39:31\u201340.","journal-title":"Saudi J Ophthalmol"},{"key":"3835_CR10","doi-asserted-by":"publisher","unstructured":"Thorne JE, Woreta F, Kedhar SR et al. Juvenile Idiopathic Arthritis-Associated Uveitis: Incidence of Ocular Complications and Visual Acuity Loss. Am J Ophthalmol. 2007;143. https:\/\/doi.org\/10.1016\/j.ajo.2007.01.033.\u00a0Epub ahead of print.","DOI":"10.1016\/j.ajo.2007.01.033"},{"key":"3835_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ajo.2006.11.025","volume":"143","author":"F Woreta","year":"2007","unstructured":"Woreta F, Thorne JE, Jabs DA, et al. Risk Factors for Ocular Complications and Poor Visual Acuity at Presentation Among Patients With Uveitis Associated With Juvenile Idiopathic Arthritis. Am J Ophthalmol. 2007;143:647\u201356.","journal-title":"Am J Ophthalmol"},{"key":"3835_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3109\/09273948.2013.791701","volume":"21","author":"A Heiligenhaus","year":"2013","unstructured":"Heiligenhaus A, Heinz C, Edelsten C, et al. Review for disease of the year: Epidemiology of juvenile idiopathic arthritis and its associated uveitis: The probable risk factors. Ocul Immunol Inflamm. 2013;21:180\u201391.","journal-title":"Ocul Immunol Inflamm"},{"key":"3835_CR13","doi-asserted-by":"publisher","unstructured":"Kim J, Park MS, Kwon S et al. Clinical Features and Risk Factors of Uveitis in Korean Children with Juvenile Idiopathic Arthritis: A Retrospective Cohort Study. J Clin Med. 2023;12. https:\/\/doi.org\/10.3390\/jcm12103438.\u00a0Epub ahead of print.","DOI":"10.3390\/jcm12103438"},{"key":"3835_CR14","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/art.42955","volume":"76","author":"M Tordoff","year":"2024","unstructured":"Tordoff M, Smith SL, Lawson-Tovey S, et al. Integration of Genetic and Clinical Risk Factors for Risk Classification of Uveitis in Patients With Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2024;76:1789\u201396.","journal-title":"Arthritis Rheumatol"},{"key":"3835_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/rheumatology\/kem053","volume":"46","author":"A Heiligenhaus","year":"2007","unstructured":"Heiligenhaus A, Niewerth M, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: Suggested modification of the current screening guidelines. Rheumatology. 2007;46:1015\u20139.","journal-title":"Rheumatology"},{"key":"3835_CR16","first-page":"2071","volume":"108","author":"K Kotaniemi","year":"2001","unstructured":"Kotaniemi K, Kautiainen H, Karma A, et al. Occurrence of Uveitis in Recently. Am Acad Ophthalmol. 2001;108:2071\u20135.","journal-title":"Am Acad Ophthalmol"},{"key":"3835_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2023.1183535","volume":"10","author":"KA Fenton","year":"2023","unstructured":"Fenton KA, Pedersen HL. Advanced methods and novel biomarkers in autoimmune diseases \u2013 a review of the recent years progress in systemic lupus erythematosus. Front Med. 2023;10:1\u201314.","journal-title":"Front Med"},{"key":"3835_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3899\/jrheum.2023-0334","volume":"51","author":"LJ O\u2019Neil","year":"2024","unstructured":"O\u2019Neil LJ, Alp\u00edzar-Rodr\u00edguez D, Deane KD. Rheumatoid Arthritis: The Continuum of Disease and Strategies for Prediction, Early Intervention, and Prevention. J Rheumatol. 2024;51:337\u201349.","journal-title":"J Rheumatol"},{"key":"3835_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cccn.2004.02.023","volume":"344","author":"D Foell","year":"2004","unstructured":"Foell D, Frosch M, Sorg C, et al. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta. 2004;344:37\u201351.","journal-title":"Clin Chim Acta"},{"key":"3835_CR20","doi-asserted-by":"publisher","first-page":"103086","DOI":"10.1016\/j.autrev.2022.103086","volume":"21","author":"JA Storwick","year":"2022","unstructured":"Storwick JA, Brett AC, Buhler K, et al. Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: A systematic review and meta-analysis. Autoimmun Rev. 2022;21:103086.","journal-title":"Autoimmun Rev"},{"key":"3835_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/315179","author":"M Mahler","year":"2014","unstructured":"Mahler M, Meroni PL, Bossuyt X, et al. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014. https:\/\/doi.org\/10.1155\/2014\/315179. Epub ahead of print 2014.","journal-title":"J Immunol Res"},{"key":"3835_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/art.30084","volume":"63","author":"HA Mariz","year":"2011","unstructured":"Mariz HA, Sato EI, Barbosa SH, et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:191\u2013200.","journal-title":"Arthritis Rheum"},{"key":"3835_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41927-023-00349-4","volume":"7","author":"JT Zanussi","year":"2023","unstructured":"Zanussi JT, Zhao J, Wei WQ, et al. Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease. BMC Rheumatol. 2023;7:1\u201311.","journal-title":"BMC Rheumatol"},{"key":"3835_CR24","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.3899\/jrheum.150567","volume":"42","author":"H Schmeling","year":"2015","unstructured":"Schmeling H, Mahler M, Levy DM, et al. Autoantibodies to dense fine speckles in pediatric diseases and controls. J Rheumatol. 2015;42:2419\u201326.","journal-title":"J Rheumatol"},{"key":"3835_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00384","volume":"10","author":"OC Kwon","year":"2019","unstructured":"Kwon OC, Lee EJ, Lee JY, et al. Prefoldin 5 and anti-prefoldin 5 antibodies as biomarkers for uveitis in ankylosing spondylitis. Front Immunol. 2019;10:1\u20137.","journal-title":"Front Immunol"},{"key":"3835_CR26","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3899\/jrheum.081318","volume":"36","author":"EB Nordal","year":"2009","unstructured":"Nordal EB, Songstad NT, Berntson L, et al. Biomarkers of chronic uveitis in juvenile idiopathic arthritis: Predictive value of antihistone antibodies and antinuclear antibodies. J Rheumatol. 2009;36:1737\u201343.","journal-title":"J Rheumatol"},{"key":"3835_CR27","first-page":"975","volume":"58","author":"A Heiligenhaus","year":"2019","unstructured":"Heiligenhaus A, Klotsche J, Tappeiner C, et al. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: Data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study. Rheumatol (United Kingdom). 2019;58:975\u201386.","journal-title":"Rheumatol (United Kingdom)"},{"key":"3835_CR28","doi-asserted-by":"publisher","unstructured":"Baquet-Walscheid K, Minden K, Niewerth M, et al. Course of uveitis in children with juvenile idiopathic arthritis (JIA): Five years follow-up data from a prospective multicenter Inception Cohort of Newly diagnosed patients with JIA (ICON-JIA) study. Arthritis Res Ther. 2025;27. https:\/\/doi.org\/10.1186\/s13075-025-03531-w. Epub ahead of print.","DOI":"10.1186\/s13075-025-03531-w"},{"key":"3835_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Care Res. 2009;61:658\u201366.","journal-title":"Arthritis Care Res"},{"key":"3835_CR30","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/art.41879","volume":"73","author":"C Trincianti","year":"2021","unstructured":"Trincianti C, Van Dijkhuizen EHP, Alongi A, et al. Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2021;73:1966\u201375.","journal-title":"Arthritis Rheumatol"},{"key":"3835_CR31","unstructured":"International Consensus on Antinuclear Antibody Patterns (ICAP). ANA Patterns - Nuclear Patterns, Icap. 2015. https:\/\/www.anapatterns.org\/nuclear_patterns.php."},{"key":"3835_CR32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/jalm\/jfab140","volume":"7","author":"EKL Chan","year":"2022","unstructured":"Chan EKL, Von M\u00fchlen CA, Fritzler MJ, et al. The International Consensus on ANA Patterns (ICAP) in 2021 - The 6thWorkshop and Current Perspectives. J Appl Lab Med. 2022;7:322\u201330.","journal-title":"J Appl Lab Med"},{"key":"3835_CR33","doi-asserted-by":"publisher","unstructured":"Amlani A, Choi MY, Tarnopolsky M et al. Anti-NT5C1A autoantibodies as biomarkers in inclusion body myositis. Front Immunol. 2019;10. https:\/\/doi.org\/10.3389\/fimmu.2019.00745. Epub ahead of print.","DOI":"10.3389\/fimmu.2019.00745"},{"key":"3835_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am J Epidemiol. 2004;159:702\u20136.","journal-title":"Am J Epidemiol"},{"key":"3835_CR35","doi-asserted-by":"crossref","unstructured":"DeLong Elizabeth C-PD. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u2013845.","DOI":"10.2307\/2531595"},{"key":"3835_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina MJ, D\u2019Agostino Sr RB, D\u2019Agostino Jr RBVR. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statistics in medicine. Stat Med. 2008;27:157\u201372.","journal-title":"Stat Med"},{"key":"3835_CR37","unstructured":"SAS Institute Inc. Base SAS\u00ae 9.3 procedures guide: statistical procedures. 2011."},{"key":"3835_CR38","first-page":"52","volume":"71","author":"A Cosickic","year":"2017","unstructured":"Cosickic A, Halilbasic M, Selimovic A, et al. Uveitis Associated with Juvenile Idiopathic Arthritis, our Observations. Med Arch (Sarajevo Bosnia Herzegovina. 2017;71:52\u20135.","journal-title":"Med Arch (Sarajevo Bosnia Herzegovina"},{"key":"3835_CR39","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/art.40544","volume":"70","author":"C Tappeiner","year":"2018","unstructured":"Tappeiner C, Klotsche J, Sengler C, et al. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study. Arthritis Rheumatol. 2018;70:1685\u201394.","journal-title":"Arthritis Rheumatol"},{"key":"3835_CR40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.31688\/ABMU.2024.59.4.12","volume":"59","author":"E Golubenco","year":"2024","unstructured":"Golubenco E, Dolapciu E, Gaidarji O, et al. Biomarkers of Uveitis in Juvenile Idiopathic Arthritis: a Systematic Review. Arch Balk Med Union. 2024;59:415\u201324.","journal-title":"Arch Balk Med Union"},{"key":"3835_CR41","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2018-213131","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: The SHARE initiative. Ann Rheum Dis. 2018;77:1107\u201317.","journal-title":"Ann Rheum Dis"},{"key":"3835_CR42","doi-asserted-by":"publisher","first-page":"103608","DOI":"10.1016\/j.autrev.2024.103608","volume":"23","author":"LEC Andrade","year":"2024","unstructured":"Andrade LEC, Klotz W, Herold M, et al. Reflecting on a decade of the international consensus on ANA patterns (ICAP): Accomplishments and challenges from the perspective of the 7th ICAP workshop. Autoimmun Rev. 2024;23:103608.","journal-title":"Autoimmun Rev"},{"key":"3835_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.730102","volume":"12","author":"N R\u00f6ber","year":"2021","unstructured":"R\u00f6ber N, Dellavance A, Ing\u00e9nito F, et al. Strong Association of the Myriad Discrete Speckled Nuclear Pattern With Anti-SS-A\/Ro60 Antibodies: Consensus Experience of Four International Expert Centers. Front Immunol. 2021;12:1\u201314.","journal-title":"Front Immunol"},{"key":"3835_CR44","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/mr\/roaf011","volume":"35","author":"S Sener","year":"2025","unstructured":"Sener S, Batu ED, Aliyev E, et al. Antinuclear antibodies staining patterns and titres in juvenile idiopathic arthritis. Mod Rheumatol. 2025;35:762\u20136.","journal-title":"Mod Rheumatol"},{"key":"3835_CR45","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4274\/MMJ.galenos.2025.05490","volume":"40","author":"L KORU","year":"2025","unstructured":"KORU L, ESEN F, CELIKEL K, et al. Anti-Nuclear Antibody Staining Patterns in Juvenile Idiopathic Arthritis: Association of AC-1 Pattern and Elevated Titers with Uveitis. Medeni Med J. 2025;40:180\u20136.","journal-title":"Medeni Med J"},{"key":"3835_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2021.816214","volume":"9","author":"I Tahmaz","year":"2022","unstructured":"Tahmaz I, Shahmoradi Ghahe S, Topf U. Prefoldin Function in Cellular Protein Homeostasis and Human Diseases. Front Cell Dev Biol. 2022;9:1\u201316.","journal-title":"Front Cell Dev Biol"},{"key":"3835_CR47","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/art.1780360615","volume":"36","author":"RW Burlingame","year":"1993","unstructured":"Burlingame RW, Rubin RL, Rosenberg AM. Autoantibodies to chromatin components in juvenile rheumatoid arthritis. Arthritis Rheum. 1993;36:836\u201341.","journal-title":"Arthritis Rheum"},{"key":"3835_CR48","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.23871","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis\u2013Associated Uveitis. Arthritis Care Res. 2019;71:703\u201316.","journal-title":"Arthritis Care Res"},{"key":"3835_CR49","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.ophtha.2022.03.014","volume":"129","author":"Z Zhong","year":"2022","unstructured":"Zhong Z, Ding J, Su G, et al. Genetic and Clinical Features of Blau Syndrome among Chinese Patients with Uveitis. Ophthalmology. 2022;129:821\u20138.","journal-title":"Ophthalmology"},{"key":"3835_CR50","doi-asserted-by":"publisher","unstructured":"Zhong Z, Dai L, Ding J, et al. Molecular diagnostic yield for Blau syndrome in previously diagnosed juvenile idiopathic arthritis with uveitis or cutaneous lesions. Br Soc Rheumatol. 2024;63:260\u20138. PMID: 37941393. https:\/\/doi.org\/10.1093\/rheumatology\/kead596.","DOI":"10.1093\/rheumatology\/kead596"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03835-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03835-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03835-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:45:05Z","timestamp":1784594705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03835-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3835"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03835-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ICON study was approved by the ethics committee of Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Germany (EA1\/056\/10). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from parents or legal guardians, and from patients aged\u2009\u2265\u20098 years, as applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HS: Supported for Industry sponsored clinical trials by Pfizer, AbbVie, UCB and advisory board member of Sanofi.FD: Received speaker\u2019s honoraria from Abbvie, Novartis, Pfizer, advisory board member for Fresenius Kabi and Novartis.DF: Honoraria for presentations from Novartis and Sobi; advisory board member of Boehringer, Novartis and Sobi.AHe: has received research grants from BMBF (FKZ, 01ER1504C), DFG (He 1877\/24-1), and honorary by Pfizer, MSD Sharp and Dohme, and Santen.GH: Personal fee from Abbvie, GSK, Lilly, Novartis, Pfizer, Sobi TK: Honoraria from Sobi to institutional accountsMJF: Medical Director of Mitogen Diagnostics Corp and consultant to Werfen and ThermoFisher.KM: Honoraria for presentations or summaries from Amgen, BMS, Biogen, Medac, Novartis, and advisory board member of AbbVie.JK, BOA, IF JPH, AH, JK, KM, PTO, CR, FW, DW: None.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"144"}}